Jul 30, 2018

Be wary of Alzheimer’s breakthroughs

Photo: Dominick Reuter/AFP/Getty Images

A promising new drug called BAN2401 generated a lot of excitement after a clinical trial found it slowed the progression of Alzheimer’s by 30%, but recent revelations have left investors and doctors with more questions than answers, reports Bloomberg.

The bottom line: Whenever you hear about a promising new Alzheimer’s treatment, make a mental note to check back in a few months — or even a few days — to see if it’s still worth your attention.

The details: High doses of the drug, which is being developed by Biogen Inc. and Eisai Co., seemed to get results, but lower doses didn’t show any benefit. It turned out that people with a gene mutation that’s associated with Alzheimer’s were kept out of the high-dose group, at the request of regulators. That made it harder to tell whether the results for the high-dose group actually meant anything.

Go deeper: Alzheimer's research yields some promising results.

Go deeper

Axios Dashboard

Keep up with breaking news throughout the day — sign up for our alerts.

What to watch in tonight's debate

Bernie Sanders at a campaign rally in Colorado. Photo: Helen H. Richardson/MediaNews Group/The Denver Post via Getty Images

Bernie Sanders is now the clear front-runner for the Democratic presidential nomination, and his opponents are ready to try to knock him down at tonight's debate in Charleston, South Carolina — especially Michael Bloomberg, who was the punching bag at the Las Vegas debate.

Why it matters: This is the last debate before Super Tuesday, when Sanders is expected to win California and Texas and could secure an insurmountable lead for the Democratic nomination. That's a direct threat to the entire field, but especially to Bloomberg, who skipped the early states to focus on the March 3 contests.

Bob Iger to step down as CEO of Disney

Photo: Jeff Kravitz/FilmMagic

The Walt Disney Company said Tuesday that it had named longtime Disney executive Bob Chapek as CEO Bob Iger's successor, effectively immediately. Iger will remain executive chairman of the company through 2021.

Why it matters: Iger is credited with having successfully turned around Disney’s animation and studio businesses and with the strategic acquisition of Marvel, Pixar, Lucasfilm and 21st Century Fox. Most recently, he was the person behind Disney's successful launch of its Netflix rival Disney+.